Get the Stockscreener App
105.35
1.47%
-1.57
After Hours:
105.35
Halozyme Therapeutics Inc stock is traded at $105.35, with a volume of 1.68M.
It is down -1.47% in the last 24 hours and up +26.25% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$106.92
Open:
$106.45
24h Volume:
1.68M
Relative Volume:
0.84
Market Cap:
$11.96B
Revenue:
$1.51B
Net Income/Loss:
$348.84M
P/E Ratio:
37.89
EPS:
2.7805
Net Cash Flow:
$667.65M
1W Performance:
-2.61%
1M Performance:
+26.25%
6M Performance:
+51.52%
1Y Performance:
+44.69%
1-Day Range:
$104.70
$106.81
1-Week Range:
$104.70
$109.66
52-Week Range:
$61.23
$109.66
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
105.35 | 12.04B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
New Halozyme (NASDAQ: HALO) director logs zero stock in first ownership filing - Stock Titan
HALO Stock Rises 36% in a Month: Here's What You Should Know - TradingView
Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued? - Sahm
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme CEO Helen Torley sells $6.28m in company shares By Investing.com - Investing.com Australia
Halozyme CEO Helen Torley sells $6.28m in company shares - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares - Stock Titan
Halozyme (HALO) Levels: Moves 2.60% Up to $107.62 in the Latest Reading; Range View: Price Remains Between $102.24 Support and $113.00 Resistance for the Current SessionInsider Buying Alerts - Vinanet
Halozyme Appoints Dannielle Appelhans to Board of Directors - The Globe and Mail
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Appoints Dannielle Appelhans to Board of Directors - Kalkine Media
Halozyme Therapeutics (NASDAQ:HALO): What Is Driving the Rally? - Kalkine Media
Halozyme adds Dannielle Appelhans to board of directors - Investing.com
Halozyme adds Dannielle Appelhans to board of directors By Investing.com - Investing.com Australia
Halozyme Therapeutics stock hits all-time high of 104.86 USD By Investing.com - Investing.com Australia
Halozyme Appoints Dannielle Appelhans to its Board of Directors - PR Newswire
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Halozyme Therapeutics stock hits all-time high of 104.86 USD - Investing.com
H.C. Wainwright reiterates Halozyme stock rating on partner data By Investing.com - Investing.com Canada
HALO Q2 2026 Earnings: EPS Surges 21.75% Above Estimates, Shares Climb 4.4%New Analyst Coverage - Vinanet
Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals - Stock Titan
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO|Halozyme Therapeutics Inc|Price:104.890|Chg%:+1.890 - TradingKey
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call - Yahoo Finance
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Halozyme (HALO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week HighHere's What Happened - MarketBeat
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Australia
Halozyme Therapeutics (HALO) Director Bernadette Connaughton Sel - GuruFocus
Halozyme director Connaughton sells $167,152 in shares By Investing.com - Investing.com Nigeria
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock - MarketBeat
Halozyme director Connaughton sells $167,152 in shares - Investing.com
Halozyme Therapeutics (HALO) affiliate plans stock option-related share sales in Form 144 - Stock Titan
Halozyme Therapeutics (HALO) director sells 1,626 shares in Rule 10b5-1 plan trade - Stock Titan
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - Yahoo Finance
What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation - Sahm
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know - Yahoo Finance
Halozyme Therapeutics (HALO) insider schedules 1,626-share stock sale via trading plan - Stock Titan
Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE DealsHas The Bull Case Changed? - Sahm
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Aug 18 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 19 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 19 '26 |
Sale |
107.00 |
20,000 |
2,139,976 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 18 '26 |
Sale |
104.18 |
20,000 |
2,083,525 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 17 '26 |
Sale |
102.60 |
20,000 |
2,052,091 |
767,780 |
8.37%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):